Startseite Kongressberichte & Archiv ESMO World Congress on Gastrointestinal Cancer Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 1

Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 1

SO-001: Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer
Shigenori Kadowaki, et al.

The conclusion from authors abstract:

Nivo combined with PTX plus Ram demonstrated promising antitumor activity as the 2nd-line treatment for AGC pts with manageable toxicities. (UMIN000025947)

 

SO-002: Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)
Ian Chau, et al.

The conclusion from authors abstract:

Final results from the cohort with G/GEJ adenocarcinoma demonstrate that a proportion of patients treated with ramucirumab and pembrolizumab in the first-line setting had prolonged disease control and survival, with no new safety signals from the combination.



SO-003: Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: Preliminary Results
Ignacio Matos, et al.

The conclusion from authors abstract: 

Debio 1347 demonstrated promising antitumor activity in patients with GI cancers harboring FGFR fusions, with an acceptable initial safety profile. The FUZE clinical trial of Debio 1347 for patients with advanced solid tumors harboring FGFR fusions includes patients with GI cancers (NCT03834220).



SO-004: A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Marina Maglakelidze, et al.

The conclusion from authors abstract:

IMU-131 is a promising B-Cell vaccine against HER2. Further work in a controlled phase 2 trial is ongoing.


SO-005: A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC)
Zev Wainberg, et al.

The conclusion from authors abstract:

In the first-line treatment of patients with mPAC, NAPOX (nal-IRI 50 mg/m2 (FBE), OX 60 mg/m2, LV 400 mg/m2, and 5-FU 2400 mg/m2) appears manageable, with promising anti-tumor activity (DCR16wk of 71.9%, sum of CR+PR+SD: 81.3%, and ORR of 34%) warranting further clinical assessment. This study is ongoing, with additional analyses planned.



SO-006: Hafnium oxide nanoparticles activated by SBRT: a new interventional radiation therapy approach for the treatment of unresectable liver cancers
Thierry De Baere, et al.

The conclusion from authors abstract:

NBTXR3 was well tolerated up to the 33% dose level and demonstrated a very good safety profile. The recruitment is ongoing at 42%. In patients with unresectable liver tumors and liver dysfunction limiting treatment options, the physics-based NBTXR3 mode of action may thus constitute a valuable solution.